The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses

Our objective was to evaluate the immunogenicity of branded and biosimilar infliximab by detecting changes in T-helper-9 (Th9) percentages induced by an in vitro stimulation test. Methods: Peripheral blood mononuclear cells collected from 55 consecutive rheumatoid arthritis (RA) outpatients (15 drug...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Mol Sci
Päätekijät: Talotta, Rossella, Berzi, Angela, Doria, Andrea, Batticciotto, Alberto, Ditto, Maria Chiara, Atzeni, Fabiola, Sarzi-Puttini, Piercarlo, Trabattoni, Daria
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5666809/
https://ncbi.nlm.nih.gov/pubmed/29023386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18102127
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia